熊去氧胆酸联合复方鳖甲软肝片治疗早中期原发性胆汁性肝硬化的临床疗效  

Clinical effects of ursodeoxycholic acid combined with compound Biejia Ruangan tablets in treatment of the early- or mid-stage primary biliary cirrhosis

作　　者：张珊珊[1] 李娅[1] 徐峰[1] 

机构地区：[1]郑州大学第一附属医院消化内科,河南省郑州市450052

出　　处：《世界华人消化杂志》2015年第26期4251-4255,共5页World Chinese Journal of Digestology

摘　　要：目的:观察熊去氧胆酸(ursodeoxycholic acid,UDCA)联合复方鳖甲软肝片对早中期原发性胆汁性肝硬化(primary biliary cirrhosis,PBC)的临床疗效.方法:将64例早中期PBC患者随机分为对照组和治疗组,各32例,两组均给予保肝退黄基础治疗,对照组在此基础上给予UDCA,治疗组在此基础上给予UDCA及复方鳖甲软肝片.1年后观察治疗前后患者肝功能[谷丙转氨酶(alanine transaminase,ALT)、谷草转氨酶(aspartate transaminase,AST)、碱性磷酸酶(alkaline phosphatase,ALP)、γ-谷氨酰转移酶(γ-glutamyl transpeptidase,GGT)、总胆红素(total bilirubin,TBIL)]、肝纤维化指标[透明质酸酶(hyaluronic acid,HA)、层钻连蛋白(laminin,LN)、Ⅲ型前胶原(precollagen typeⅢ,PⅢNP)、Ⅳ型胶原(typeⅣcollagen,PIVP)]及临床症状和体征变化.结果:治疗组及对照组患者血清生化指标ALT、AST、GGT、ALP、TBIL均有显著下降,与治疗前相比差异有统计学意义(均P<0.05),治疗后两组患者比较,治疗组血清生化指标GGT、ALP、TBIL和肝纤维化指标HA、LN、PⅢNP,PⅣP较对照组显著下降,两组相比差异有统计学意义(均P<0.05).治疗后两组患者在改善临床症状和体征上差异有统计学意义(P<0.05).结论:熊去氧胆酸联合复方鳖甲软肝片可明显改善早中期PBC患者肝功能、肝纤维化指标及临床症状和体征.AIM：To observe the clinical effects of ursodeoxycholic acid（UDCA） combined with compound Biejia Ruangan tablets in the treatment of early-or mid-stage primary biliary cirrhosis（PBC）.METHODS：Sixty-four patients with early- or mid-stage PBC were randomly divided into a control group and a treatment group,with32 cases in each group.Both groups were given hepatoprotective and jaundice-relieving treatments.The control group was additionally given UDCA,and the treatment group was additionally given UDCA combined with compound Biejia Ruangan tablets.After one year,the changes in liver function markers[alanine transaminase（ALT）,aspartate transaminase（AST）,alkaline phosphatase（ALP）,γ-glutamyl transpeptidase（GGT）,total bilirubin（TBIL）],liver fibrosis markers[hyaluronic acid（HA）,laminim（LN）,precollagen type Ⅲ（PⅢNP）,type Ⅳ collagen（PIVP）]and clinical symptoms and signs were compared before and after the treatment between the two groups.RESULTS：The levels of ALT,AST,GGT,ALP,and TBil in both groups significantly decreased after treatment（P〈0.05）.The levels of GGT,ALP and TBIL were significantly lower in the treatment group than in the control group（P〈0.05）.The levels of liver fibrosis markers（HA,LN,PⅢNP,and PⅣP） were significantly lower in the treatment group than in the control group（P〈0.05）.The clinical symptoms and signs in the treatment group were improved significantly after treatment compared to the control group.CONCLUSION：UDCA combined with compound Biejiaruangan tablets can significantly improve liver function,liver fibrosis and clinical symptoms and signs in patients with early- or mid-stage PBC.

关 键 词：原发性胆汁性肝硬化 复方鳖甲软肝片 熊去氧胆酸 临床疗效 

分 类 号：R575.2[医药卫生—消化系统]